Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 3/20 | 0.47 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MPO | P05164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3312575 | 1.00 | CNR2 (0.51) | CNR2CNR1ACHEKAT2BFAAH | |
| SCHEMBL3316327 | 0.92 | KAT2B (0.52) | CNR2CNR1ACHEKAT2BPKM | |
| SCHEMBL12443687 | 0.90 | CNR2 (0.43) | CNR2CNR1ACHEKAT2BFAAH | |
| SCHEMBL12443253 | 0.90 | CNR2 (0.43) | CNR2CNR1ACHEKAT2BFAAH | |
| SCHEMBL14070011 | 0.86 | KAT2B (0.67) | CNR2CNR1ACHEKAT2BFAAH | |
| SCHEMBL10485351 | 0.85 | PKM (0.55) | KAT2BPKMMAPTMEN1KMT2A | |
| SCHEMBL765094 | 0.82 | KAT2B (0.46) | CNR2CNR1ACHEKAT2BPKM | |
| SCHEMBL765129 | 0.78 | KAT2B (0.42) | KAT2BPKMMAPTMEN1KMT2A | |
| SCHEMBL12443701 | 0.77 | KAT2B (0.39) | CNR2CNR1ACHEKAT2BPKM | |
| SCHEMBL10046478 | 0.75 | CNR2 (0.41) | CNR2CNR1ACHEMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278098-B2 | Substituted phthalazines for inducing insulin secretion and protecting beta-cells | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278098-B2 | Substituted phthalazines for inducing insulin secretion and protecting beta-cells | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278098-B2 | Substituted phthalazines for inducing insulin secretion and protecting beta-cells | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150164892-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2015-06-18 | — | — | US | disclosed |
| US-20150164892-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2015-06-18 | — | — | US | disclosed |
| US-20150164892-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2015-06-18 | — | — | US | disclosed |
| EP-2132183-B1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | Univ Virginia Patent Found (US) | 2015-06-03 | — | — | EP | disclosed |
| US-8871764-B2 | Lisofylline analogs and methods for use | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871764-B2 | Lisofylline analogs and methods for use | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871764-B2 | Lisofylline analogs and methods for use | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130137693-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137693-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137693-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-05-30 | — | — | US | disclosed |
| US-20100105690-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2010-04-29 | — | — | US | disclosed |
| US-20100105690-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2010-04-29 | — | — | US | disclosed |
| US-20100105690-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2010-04-29 | — | — | US | disclosed |
| EP-2132183-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | University Of Virginia Patent Foundation (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008108842-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164892-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | IAPP, RNASE1, CTSA | CNR2 4257/4885CNR1 4043/4885ACHE 252/4885 |
| US-20100105690-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | IAPP, RNASE1, CTSA | CNR2 4288/4885CNR1 4124/4885ACHE 252/4885 |
| US-20130137693-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | IAPP, RNASE1, CTSA | CNR2 4288/4885CNR1 4124/4885ACHE 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.